Amylyx Pharmaceuticals (AMLX) Net Equity Issued and Repurchased (2021)
Amylyx Pharmaceuticals (AMLX) posted quarterly Net Equity Issued and Repurchased of $209000.0 for Q4 2021, down 99.84% quarter-over-quarter from $132.7 million in Q3 2021.
Amylyx Pharmaceuticals (AMLX) Net Equity Issued and Repurchased (2021) Analysis & Trends
Amylyx Pharmaceuticals' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $209000.0 for Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 209,000.00 |
| Dec 31, 2021 | 209,000.00 |
| Sep 30, 2021 | 132.72 Mn |
| Sep 30, 2021 | 132.72 Mn |